Four drugmakers are urging a federal appeals court to affirm a lower court’s decision to dismiss a California health system’s [...] …
Year: 2024
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An organization that describes itself as being “comprised of dozens of national, public health, patient advocacy and multicultural organizations,” but [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The growth in total 340B purchases last year was largely a result of drugmaker price increases and broader healthcare trends, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A California-based healthcare startup recently announced that it has raised more than $30 million, as part of a campaign with [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The phrase “we’re scheduling an audit” generally triggers angst, tension and even fear. Audits of your 340B operations look deeply into your prescription records and billing procedures. They are complex and require a great deal of preparation and
…
The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Exclusive
Former Senior Trump Official Talks Drug Pricing Reform, Says 340B Program Is ‘Out of Control’
A key official in the former Trump administration raised serious concerns with the 340B program during the keynote address at [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An influential drug industry expert said that he expects Johnson & Johnson (J&J) to sue the government over its refusal [...] …
